Given that DAPT-induced Notch inactivation attenuated hyperglycemia-induced Nrg1 overexpression, we hypothesized that the dual inhibition of NOTCH and HER2 could effectively reduce tumor burden, especially in breast cancer patients with hyperglycemia. Here, ERBB2 is linked to breast cancer.